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Supplementary Figure exchanging the linker using restriction / ligation with KpnI-HF and SpeI-HF as described above. Constructs pET-28a(+)-TRAS-LUMABS 3 and pET-28a(+)-CD20-LUMABS-1 were obtained from pET-28a(+)-TRAS-LUMABS-2 by exchanging the linker region using restriction / ligation with KpnI-HF and SpeI-HF as described above, while pET-28a(+)-CD20-LUMABS-2 was obtained from pET-28a(+)-CD20-LUMABS-1 using Multiple Site Directed Mutagenesis as described elsewhere. 1 Correct sequences of all sensors described in this study were verified by Sanger sequencing. For Sequences of sensor proteins used in this study, see Supplementary Figures S14 and S15.
Protein Expression and Purification
Protein expression in E. coli was essentially done as previously described 2 by inducing exponentially growing BL21(DE3) cells (at an OD 600 of 0.6) with 0.1 mM IPTG at 25 °C for 16-20 hours. Purification was done by immobilized metal affinity chromatography as described. TRAS-LUMABS-2, 3 and CD20-LUMABS-1 were further purified by Strep-tactin affinity chromatography as described. CTX-LUMABS 1 and 2 were further purified by Size Exclusion Chromatography (SEC) over a 26/60 HiLoad Superdex column with a volume of 300 mL in a buffer containing 50 mM Na 2 HPO 4 / NaH 2 PO 4 (pH 7.5), 150 mM NaCl, 10% (v/v) glycerol, 1 mM EDTA, and 0.1% (v/v) Triton-X100. All proteins were frozen in liquid nitrogen and stored at -80 °C.
Peptide synthesis.
All peptides with N-terminal fluorescein groups were synthesized using Fmoc-protected solid phase peptide synthesis and labeled at the N-termini with fluorescein iso-thiocyanate via a (5-amino)-3-oxapentanoic acid (O1PEN) linker as described.
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Fluorescence Polarization measurements. 
ELISAs
The trastuzumab PK kit (Somru Bioscience, Charlottetown, Canada; SB-07-035) was used according to the instructions. Standards were prepared by serially diluting trastuzumab in PBS pH 7.4, 0.1% BSA and subsequently diluting 10-fold in pooled human plasma. Test samples were prepared in a similar way to ensure that they contained 90 % pooled human plasma. To ensure that test samples fell in the linear range of the assay, the 2.3 µM trastuzumab sample was diluted 400-fold in assay buffer, the 1.38 µM test sample was diluted 200-fold, the 500 nM and 138 nM test samples were diluted 100-fold. Calibrators and test samples were then diluted another 50-fold in assay buffer and incubated 1 hour shaking at 300 rpm in 96-well plates coated with anti-therapeutic protein provided with the kit. After three washes with the provided wash buffer, the HRP-conjugated secondary anti-trastuzumab polyclonal antibody was incubated for 1 hour shaking at room temperature. After another three washes, TMB reagent was incubated for 10 minutes at room temperature protected from light. The TMB reaction was stopped by the provided stop solution, turning the product yellow. Absorbance was read out on a Tecan Infinite F500 plate reader at 450 nm with background correction at 620 nm. A 4 parameter curve was fit through the data on a log absorbance/log concentration plot (Fig. S12 ).
The cetuximab PK kit (Somru Bioscience, Charlottetown, Canada; SBA-100-007-015) was used according to the manufacturer's instructions. Standards were prepared by serially diluting cetuximab in PBS pH 7.4, 0.1% BSA and subsequently diluting 10-fold in pooled human plasma. Test samples were prepared in a similar way to ensure that they contained 90 % pooled human plasma. In accordance with the protocol, a single calibrator series was measured three times. To ensure that test samples fell in the linear range of the assay, the 2.3 µM cetuximab sample was diluted 200-fold in assay buffer, the 500 and 200 nM test samples were diluted 100 fold and the 20 nM sample was diluted 10-fold. Calibrators and test samples were then diluted another 100-fold in assay buffer and incubated 1 hour shaking at 300 rpm in 96-well plates coated with the extracellular domain III of EGFR provided with the kit. After three washes with the provided wash buffer, the HRP-conjugated secondary anti-cetuximab antibody was incubated for 1 hour shaking at room temperature. After another three washes, TMB reagent was incubated for 10 minutes protected from light. The TMB reaction was stopped by the provided stop solution, turning the product yellow. Absorbance was read out on a Tecan Infinite F500 plate reader at 492 nm. A straight line was fit through the data on a Log absorbance / Log concentration plot (equation S1) log 10 = 0.44 log 10 [cetuximab] + 3.03
Equation S1
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The original calibrator concentration was used here. Each test sample was measured six times. For each individual measurement a concentration was calculated using the calibration line and its dilution factor and the mean and SD were calculated from these derived concentrations. Statistics were done in Microsoft Excel. Pearson's R between test samples measured by ELISA and LUMABS was determined by linear regression and statistical significance was determined from the ANOVA test.
Thermodynamic model
The model is schematically shown in Figure 1A in the main text and is an adaptation from a previously published model for a different type of antibody sensor. 4 The equilibrium constants for each step were defined as K 1 for monovalent antibody binding, K 2 for disrupting the helper interaction and K 3 for formation of the bivalent complex. The inverse equilibrium constants (K 1 ', K 2 ' and K 3 ', where
are for the reverse steps. K 1 is solely determined by the monovalent antibodyepitope affinity K d.Ab and a factor 4 (the number of possible combinations of any of the two antigen binding sites interacting with any of the two epitopes).
K 2 is determined by both the monovalent affinity of this interaction and the effective local concentration of proline rich peptide near the SH3 domain C eff.helper .
K 3 is determined by K d.Ab and the effective local concentration of epitope near the second antigen binding domain C eff.Ab and a factor 2 (the number of possible states with a single epitope bound to the antibody).
The overall apparent dissociation constant of the sensor,
The emission ratio as a function of antibody concentration was defined as the emission ratio of each state S (ER S ) multiplied by the fraction of the sensor that resides in this state, f S , and then summed over all states. In doing so, the model assumes that the sensor concentration is always much lower than
The numbering of the five different states is indicated in figure 1A in the main text. 
The dynamic range of the sensor can be written as:
The subscripts 0 and ∞ denote the emission ratios at respectively zero and saturating antibody concentrations. The maximally possible dynamic range (under the assumption that the sensor will be completely closed in the absence of antibody and completely in the bivalent state under saturating conditions is:
The Figure S1 ) both local concentrations were first set at 1 mM. C eff.helper was then multiplied by the square root of a varying number (indicated in the legend) while C eff.Ab was divided by the square root of the same number. For each ratio, K d.Ab was then varied from 10 nM to 86 µM. K d.app was calculated using equation 3 and DR / DR max was calculated using equations S5 and S6. Curves in Figure 1B in the main text were generated with a ratio of 10, meaning that C eff.helper was √10 mM and C eff.Ab was 1 / √10 mM. This was in good agreement with the experimental curves. It is difficult to predict these concentrations precisely, but the estimate is reasonable, given that Intramolecular interaction partners are known to have effective local concentrations in the high micromolar to low millimolar range 6, 7 and that flexible linkers span shorter distances far more readily than longer ones.
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Supplementary Figure S1 . Plots of DR / DR max vs. K d.app for different C eff.helper / C eff.Ab . Both effective concentrations were first set at 1 mM. Then, C eff.helper was multiplied by the square root of the ratio indicated in the legend, while C eff.Ab was divided by the same ratio. For example, a ratio of 10 means C eff.helper is √10 mM and C eff.Ab is 1 √10 ⁄ mM. For each ratio, K d.app and DR / DR max were calculated with varying K d.Ab values ranging from 10 nM to 86 µM using equations 3, S5 and S6. These are shown on the horizontal and vertical axis respectively. The decline in dynamic range occurs at higher K d.app for lower C eff.helper / C eff.Ab ratios. However, when the ratio is very low (e.g. 0.1), another effect is seen, namely that the sensor does not fully close even in the absence of antibody. Figure 4 in the main text. 
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TRAS-LUMABS-1 atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccatatggctagcgacgacaacttt M G S S H H H H H H S S G L V P R G S H M A S D D N F
atatacaaggcgaaggcgctctatccctatgatgcagatgatgatgacgcatacgaaatctcattcgaacaaaatgaaatc I Y K A K A L Y P Y D A D D D D A Y E I S F E Q N E I cttcaggtatcagacattgaggggcggtggtggaaagcccgccgcgccaatggagagacaggcatcatcccgtcgaattat L Q V S D I E G R W W K A R R A N G E T G I I P S N Y gttcagttgattgacggtcctgaggaaatgcatcggggcggctcgggaggctcaggcagccatatggtaagtaaaggtgaa V Q L I D G P E E M H R G G S G G S G S H M V S K G E gaagacaatatggcttctctgcctgccacacatgagcttcatatttttgggagcataaacggagtggatttcgacatggta E D N M A S L P A T H E L H I F G S I N G V D F D M V ggtcagggtacggggaaccctaacgatggatatgaggagttgaatcttaaaagcacaaagggtgatctgcagttctcgccc G Q G T G N P N D G Y E E L N L K S T K G D L Q F S P tggatcctggtgccgcatataggttatggtttccatcagtatcttccatacccggatggcatgagcccttttcaggccgca W I L V P H I G Y G F H Q Y L P Y P D G M S P F Q A A atggtagatggctcaggatatcaagtgcatcggaccatgcagtttgaagatggggcgtctttgacggtaaattacaggtac M V D G S G Y Q V H R T M Q F E D G A S L T V N Y R Y acctatgagggtagccatataaagggagaagcgcaggtgaagggaactggattcccagcggatggcccagtcatgacaaac T Y E G S H I K G E A Q V K G T G F P A D G P V M T N agcctcaccgctgctgattggtgccgatccaagaaaacgtatccaaacgataaaactatcatttctacttttaagtggtcc S L T A A D W C R S K K T Y P N D K T I I S T F K W S tatacaacaggaaacgggaaacgctatcgttcaacggcccgcacgacctacacgtttgcaaagccaatggctgcgaattat Y T T G N G K R Y R S T A R T T Y T F A K P M A A N Y ctgaaaaaccagccgatgtatgtgttccgtaaaaccgaactgaaacattctaaaacggagctcaatttcaaggaatggcag L K N Q P M Y V F R K T E L K H S K T E L N F K E W Q aaggcatttacggatgtcatgggaatggacgaactgtataagtcgggcggaggtacccagctgggcccgtatgaactgtgg K A F T D V M G M D E L Y K S G G G T Q L G P Y E L W gaactgagccatgggggttcgggtggttcaggcggctcaggaggctccgggggttccggagggagcggtgctgaagccgca E L S H G G S G G S G G S G G S G G S G G S G A E A A gccaaggaagcagcagctaaagaggccgctgcgaaggaagctgccgcaaaggaggcggcggcgaaagaggcggcagcaaaa A K E A A A K E A A A K E A A A K E A A A K E A A A K gccggatctggtggcagtggtggctccggcgggtcaggtggcagcgggggatcaggagctgaggcagccgccaaagaggct A G S G G S G G S G G S G G S G G S G A E A A A K E A gcggccaaggaggccgccgctaaagaagccgcggcaaaagaggcagcggcaaaggaagcggctgcgaaagccggaagtggt A A K E A A A K E A A A K E A A A K E A A A K A G S G gggtcgggcggctccggtggctctggcggcagtggcggtagtggcgggcaattagggccatacgagttatgggagttatca G S G G S G G S G G S G G S G G Q L G P Y E L W E L S cacactagtggaggcagcatggtatttactcttgaagattttgtcggtgattggcgccagaccgccggctataacctggac H T S G G S M V F T L E D F V G D W R Q T A G Y N L D caagtgcttgaacagggcggggttagcagcctgtttcaaaacctgggggtgagtgtcacgccaattcagcgcatcgttctg Q V L E Q G G V S S L F Q N L G V S V T P I Q R I V L tcgggagagaatggtctgaaaatcgatatccacgtcattatcccgtacgaaggtctttctggtgatcagatggggcagata S G E N G L K I D I H V I I P Y E G L S G D Q M G Q I gaaaaaatattcaaagtggtgtacccagtagacgatcatcacttcaaggttatactgcactatggcaccctcgttatcgat E K I F K V V Y P V D D H H F K V I L H Y G T L V I D ggcgttactccgaatatgatcgattactttgggcgtccttatgaaggtattgcggtgttcgacggtaaaaaaattacggtt G V T P N M I D Y F G R P Y E G I A V F D G K K I T V accgggacgctctggaatggtaataaaatcattgatgagcgcttgataaacccagatggcagccttctgttcagagttacg T G T L W N G N K I I D E R L I N P D G S L L F R V T ataaacggggttacgggttggcgactgtgcgaaagaatattagcttctagcggtggaggatctattcgttcaaagccgctg I N G V T G W R L C E R I L A S S G G G S I R S K P L ccacccctacccgtgtaatag P P L P V --
